Use of testosterone to prevent cyclophosphamide-induced azoospermia

Annals of Internal Medicine

Volumn 126, Issue 4, 1997, Pages 292-295

  Masala, Antonio ^b   Faedda, Rossana ^b   Alagna, Sergio ^b   Satta, Andrea ^b   Chiarelli, Giorgio ^b   Rovasio, Pier Paolo ^b   Ivaldi, Riccardo ^b   Taras, Marianna Simona ^b   Lai, Elisabetta ^b   Bartoli, Ettore ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FOLLITROPIN; LUTEINIZING HORMONE; TESTOSTERONE;

ADULT; ARTICLE; AZOOSPERMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FOLLITROPIN BLOOD LEVEL; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUTEINIZING HORMONE BLOOD LEVEL; MALE; NEPHROTIC SYNDROME; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPERMATOZOON COUNT;

EID: 0031058371     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-4-199702150-00005     Document Type: Article

References (20)

1. Shalet S, Clayton PE. Price DA. Growth and pituitary function in children treated for brain tumours or acute lymphoblastic leukaemia. Horm Res. 1988; 30:53-61.
2. Cohen A, Van-Lint MT, Lavagetto A, Chiodi S, Spinelli S. Bacigalupo A, et al. Pubertal development and fertility in children after bone marrow transplantation. Bone Marrow Transplant. 1991;8(Suppl 1):16-20.
3. Averette HE, Boike GM, Jarrell MA. Effects of cancer chemotherapy on gonadal function and reproductive capacity. CA Cancer J Clin. 1990;40:199-209.
4. Sklar CA, Kim TH, Ramsay NK. Thyroid function among long-term survivors of bone marrow transplantation. Am J Med. 1982;73:688-94.
5. Masala A, Alagna S, Gallisai D, Burrai C, Rovasio PP, Ginanni A, et al. Thyroid function in thalassemic patients after bone marrow transplantation. J Nucl Biol Med. 1994;38:266-7.
6. Watson AR, Ranee CP, Bain J. Long term effects of cydophosphamide on testicular function. Br Med J. 1985;291:1457-60.
7. Fairley KF, Barrie JU, Johnson W. Sterility and testicular atrophy related to cydophosphamide therapy. Lancet. 1972;1:568-9.
8. Rivkees SA, Crawford JD. The relationship of gonadal activity and chemotherapy-induced gonadal damage. JAMA. 1988;259:2123-5.
9. Heimpel H, Arnold R, Hetzel WD, Hueske D, Kreuser ED, Wirthenson EF, et al. Gonadal function after bone marrow transplantation in adult male and female patients. Bone Marrow Transplant. 1991;8(Suppl 1):21-4.
10. Bogdanovic R, Bankevic M, Cvoric A. Testicular function following cydophosphamide treatment for childhood nephrotic syndrome: long-term fol-low-up study. Pediatr Nephrol. 1990:4:451-4.
11. Faedda R, Satta A, Bosincu L, Pirisi M, Bartoli E. Immune suppressive treatment of membranous glomerulonephritis. J Nephrol. 1995:8:107-12.
12. Faedda R, Palomba D, Satta A, Pirisi M, Tanda F. Bartoli E. Immunosuppressive treatment of the glomerulonephritis of systemic lupus. Clin Nephrol. 1995:44:367-75.
13. Matsumoto AM. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. J Clin Endocrinol Metab. 1990:70:282-7.
14. Cunningham GR, Silverman VE, Thornby J, Kohler PO. The potential for an androgen male contraceptive. J Clin Endocrinol Metab. 1979:49:520-6.
15. Karashima T, Zalatnai A, Serially AV. Protective effects of analogs of luteinizing hormone-releasing hormone against chemotherapy-induced testicular damage in rats. Proc Natl Acad Sci USA. 1988:85:2329-33.
16. Goodpasture JC, Bergstrom K, Vickery BH. Potentiation of the gonadotoxicity of Cytoxan in the dog by adjuvant treatment with a luteinizing hormone-releasing hormone agonist. Cancer Res. 1988:48:2174-8.
17. Kreuser ED, KlingmuUer D, Thiel E. The role of LHRH-analogues in protecting gonadal functions during chemotherapy and irradiation. Eur Urol. 1993:23:157-64.
18. Chapman RM, Sutcliffe SB. Protection of ovarian function by oral contraceptives in women receiving chemotherapy for Hodgkin's disease. Blood. 1981:58:849-51.
19. Carde P, Lejeune C, Duiloust E, Velez de la Calle JF. Mathieu-Tubiana N, Lhomme C. Analogues du LH-RH et protection contre la toxicité gonadique des traitements anticancéreux. Contrac Fertil Sexual.1989:17:445-51.
20. Johnson DH. Linde R, Hainsworth JD. Vale W. Rivier J, Stein R. et al. Effect of a luteinizing hormone-releasing hormone agonist given during combination chemotherapy on posttherapy fertility in male patients with lymphoma: preliminary observations. Blood. 1985:65:832-6.